EQT and HealthCap lead Series A for EUR 25 million for Ariceum Therapeutics
Munich — Baker McKenzie advised Ariceum Therapeutics (Ariceum) on the successful closing of a EUR 25 million Series A financing round led by EQT Life Sciences (formerly LSP) and HealthCap, and on the acquisition of assets from Ipsen Pharma.
Ariceum is a privately held biotechnology company developing a novel, first-in-class radiopharmaceutical product for the diagnosis and targeted radiation therapy of certain difficult-to-treat cancers. The company was founded by EQT Life Sciences (formerly LSP) and HealthCap, which also led the oversubscribed financing round in which Pureos Bioventuresalso participated. Ipsen transferred assets and all rights to them to the company.
“Together with our client and our team of specialized corporate, biotechnology and life sciences lawyers, we succeeded in securing financing, paving the way for the development of a therapy for patients suffering from certain difficult-to-treat cancers,” commented Julia Braun, LL.M., the lead partner on the transaction.
Ariceum is led by a highly experienced management team with a strong track record and expertise in clinical trials, systemic radiotherapy and radio-pharmaceutical development, as well as in the launch and commercialization of diagnostic and therapeutic products in a variety of indications worldwide.
Baker McKenzie’s Corporate/M&A and Life Sciences team regularly advises pharmaceutical companies, financial and strategic investors, and early-stage biotechnology companies on domestic and international healthcare transactions.
Most recently, Baker McKenzie advised, among others, Andera Partners, Evotec and Fund+ on a EUR 60 million Series B financing of Tubulis GmbH, Allecra Therapeutics on an exclusive license and supply agreement with ADVANZ PHARMA, MODAG on a strategic collaboration with Teva, Chord Therapeutics on its sale to Merck KGaA, LSP as lead investor in a EUR 20 million Series A equity financing of Innovative Molecules, Numab Therapeutics in a CHF 100 million cross-over financing, CatalYm in a EUR 50 million Series B financing led by Vesalius Capital, Casdin Capital as lead investor in DNA Script’s USD 50 million extended Series B equity financing round, and Chr. Hansen Holding in its acquisition of Jennewein Biotechnology.
Legal advisor Ariceum Therapeutics: Baker McKenzie
Lead: Corporate/M&A: Julia Braun, LL.M. (Partner, Munich)
Team: Corporate/M&A: Dr. Marcus Meese (Partner, Munich), Dr. Katja Heuterkes (Counsel, Munich), Dr. Julia Rossié (Associate, Munich)
Employment: Dr. Matthias Köhler (Partner, Berlin), Felix Arnold, Dr. Harasch Yakubi (both Associates, Berlin), Amelie Czekalla (Associate, Frankfurt)
IP: Dr. Markus Hecht (Counsel, Frankfurt)
Tax: Thomas Gierath (Partner, Munich), Viktoria Ritter (Associate, Munich), Jochen Meyer-Burow (Partner, Frankfurt), Ariane Schaaf (Counsel, Frankfurt)
About Baker McKenzie
Complex business challenges require a holistic response across different markets, sectors and jurisdictions. Baker McKenzie’s solutions for clients are accompanied by seamless advice, underpinned by in-depth practice and industry knowledge as well as excellent local market insights. In more than 70 offices worldwide, we work with our clients to provide solutions for a connected world.
In Germany, around 200 lawyers in Berlin, Düsseldorf, Frankfurt/Main and Munich represent the interests of their clients with proven professional expertise and international experience. As one of the leading German law firms, Baker McKenzie advises national and international companies and institutions in all areas of commercial law.